Clinical trial · Interventional
Communication Strategies to Increase HPV Vaccinations
A Cluster Randomized Controlled Trial Testing Communication Strategies to Increase HPV Vaccination in Primary Care
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 26, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260926-000001
Summary
Brief summary (as posted)
This research aims to identify communication strategies to improve the uptake of vaccines using an experimental design, focusing on the Human Papillomavirus (HPV) vaccine, which is highly effective in preventing HPV-related cancers. However, low HPV vaccination rates among adults remain a significant public health challenge. Although randomized controlled trials (RCTs) have demonstrated that interventions can increase vaccine uptake in children, few RCTs have been conducted among adults. To address this gap, a multidisciplinary investigative team with expertise in communication, medicine, nursing, and behavior-change intervention research will conduct a survey experiment and a cluster randomized controlled trial. First, a national sample of adults ages 18 to 45 who have not received the HPV vaccine or are unsure of their vaccination status will participate in a survey experiment to identify the most promising theory-based messages to strengthen HPV vaccine intentions. The two messages associated with the largest increases in vaccination intentions will then be selected for further testing. Next, 16 Penn Medicine primary care clinics will participate in a factorial cluster randomized controlled trial to test patient-level and clinic-level interventions designed to increase HPV vaccine uptake. Patient-level interventions will include theory-based text messages and a reminder-only message condition. The clinic-level intervention will provide healthcare providers with feedback on missed opportunities for HPV vaccination and a toolkit to support strong HPV vaccine recommendations. The study will evaluate whether these interventions increase receipt of the first HPV vaccine among eligible adult patients and whether combining patient-directed messages with the clinic-level intervention further increases HPV vaccination. HPV vaccination will be assessed using Penn Medicine electronic health records and, when needed, patient self-report.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Communication | — | UNRESOLVED | — |
| Papilloma Viral Infection | — | UNRESOLVED | — |
| Vaccine Hesitancy | — | UNRESOLVED | — |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Control Message | Behavioral | — | UNRESOLVED |
| HPV Message 1 | Behavioral | — | UNRESOLVED |
| HPV Message 2 | Behavioral | — | UNRESOLVED |
| HPV Message 3 | Behavioral | — | UNRESOLVED |
| Provider Strong-Recommendation Toolkit | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (8)
- type
- EXPERIMENTAL
- label
- HPV Message 1 + Clinic Intervention
- interventionNames
- Behavioral: HPV Message 1
- Behavioral: Provider Strong-Recommendation Toolkit
- type
- EXPERIMENTAL
- label
- HPV Message 1 + No Clinic Intervention
- interventionNames
- Behavioral: HPV Message 1
- type
- EXPERIMENTAL
- label
- HPV Message 2 + Clinic Intervention
- interventionNames
- Behavioral: HPV Message 2
- Behavioral: Provider Strong-Recommendation Toolkit
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 45 Years
Show eligibility criteria text
Inclusion Criteria: * 18-45 years old Exclusion Criteria: * Under 18 and over 45 years old * Received HPV vaccine or unsure about receipt
References
Publications (0)
Data not yet available